Episodes (Page 26)
✨
The SABI discusses herbal medicine for women's hormonal wellness.
Anna Cave-Bigley
Hilary Metcalfe
✨
Boehringer Ingelheim's potential success in MASH treatment.
✨
Key highlights from ASCO 2024 oncology conference.
✨
Sarah Karlin-Smith discusses the BIO Conference and the US BIOSECURE Act.
Sarah Karlin-Smith
✨
Trends and challenges in life sciences workforce building.
✨
Global pharmaceutical industry's outlook on the future of cancer research.
✨
Review of BIO Notebook and ASCO 2024 data highlights.
✨
Strategic developments for Teva, Sandoz, and Sawai in the generics market.
✨
Guangzuo Luo discusses Chinese biotechs expanding globally.
Guangzuo Luo
✨
JB CEO addresses rumors of stake sale.
Nikhil Chopra
✨
ASCO preview and Asahi's US acquisition.
✨
Jasper Crone explains the Corporate Sustainability Reporting Directive (CSRD).
Jasper Crone
✨
Best practices for IND applications and pre-IND meetings.
Harshini Neelakantan
Marcus Delatte
✨
Genmab's 25-year evolution as an antibody powerhouse.
✨
Claus Zieler emphasizes biopharma's role in driving healthcare change.
Claus Zieler
✨
Joan Shen discusses CNS drug development in China with NeuShen.
NeuShen's Joan Huaqiong Shen
✨
Information on the 3rd annual Citeline Japan Awards categories.
✨
Biogen's immunology acquisition and AstraZeneca's respiratory strategy.
✨
US FDA considers regulatory changes for innovative clinical trial designs.
✨
Exploring next-generation obesity treatments beyond GLP-1.